Skip to Main Content

Firm Chiefs

  • CCU

    I have been a member of the Section of Cardiovascular Medicine since completion of Cardiology fellowship in 1989. My primary interest has been clinical cardiology particularly in the areas of both Intensive Care Cardiology (serving as Medical Director of the CICU) as well as Interventional cardiology (serving as the Fellowship Director of the Interventional Cardiology Fellowship for the past 20 yrs). I have been the recipient of innumerable teaching awards both within the Yale Medical School as ell as the Department of Medicine/Section of Cardiology.

  • Goodyer Firm (Cardiology)

    I received my BA from Jackson College of Tufts University and my MD from the Cornell University Medical College. I came to Yale to do my Cardiology Fellowship (where I was the first female cardiology fellow and the first fellow who did additional training in Cardiac Electrophysiology) and have been at Yale since then. I have emphasized patient care and teaching during my career and I am the Director of the Yale Clinical Cardiac Electrophysiology Fellowship Program and Firm Chief of the Goodyer Teaching Service. My research interests have included device and drug therapy of arrhythmias, arrhythmias complicating the management of adults with congenital heart disease, atrial fibrillation, and the cardiac manifestations of sarcoidosis.

  • Fitkin Firm (General Medicine)

    Lynn E. Fiellin, M.D. is a Professor of Medicine at the Yale School of Medicine and at the Yale Child Study Center. Her work focuses on developing and testing novel videogame interventions to promote health and reduce risk in youth and young adults. She has received funding from the National Institutes of Health including NICHD, NIDA, and NIAAA, the CVS Health Foundation, the Robert Wood Johnson Foundation, the NIH/FDA, and the BEST Foundation/Conrad N. Hilton Foundation. She and her team of researchers, game developers, and community partners have and currently are creating and evaluating interactive evidence-based games addressing a number of health-related and medical issues including HIV prevention and risk reduction, HIV testing and counseling, tobacco and marijuana smoking, e-cigarette use and vaping prevention, and most recently opioid misuse prevention in adolescents. She builds collaborations and partnerships between researchers, educators, commercial game developers, and community-based organizations with the goal of developing and rigorously testing innovative, effective, and targeted game interventions, tailored for specific populations and with the scientific data behind them to demonstrate that they work.

  • Generalist Firm (General Medicine)

    Research Interests:

    Dr. O’Connor has focused his research on the interface between primary care and addiction medicine. This has included research examining the transfer of addiction treatment strategies from “specialty” settings to primary care and other general medical settings. His publications in this area include studies on the management of opioid withdrawal in primary care settings, opioid maintenance in primary care, and the use of naltrexone for treating alcohol dependence in primary care patients. He has been active in medical education on addiction both nationally and internationally and has served as the President of The Association for Medical Education and Research on Substance Abuse (AMERSA) and of the The American Board of Addiction Medicine (ABAM) and The Addiction Medicine Foundation.

    Selected Recent Publications:

    O’Connor, PG. Brief Interventions for Problem Drinking: Another Piece of the Puzzle. Annals of Internal Medicine. 2007; 146(3):223-225.

    Martell BA, O’Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, and Fiellin DA. Systematic Review: Opioid treatment for chronic back pain: prevalence, efficacy and association with addiction. Annals of Internal Medicine. 2007; 146:116-127.

    Sledge, WH, Brown, KE, Levine, JM, Fiellin, DA, Chawarski, M, White, WD, O’Connor, PG. A Randomized Trial of Primary Intensive Care to Reduce Hospital Admissions in Patients with High Utilization of Inpatient Services. Disease Management. 2006; 9(6)328-338.

    O’Connor PG. Problem Drinkers: Find Them, Keep Them, Don’t Lose Them, Treat Them. Journal of General Internal Medicine. 2005; 20(1):96-97.

    D’Onofrio G, MS; Pantalon MV, Degutis LC, Fiellin DA, O’Connor PG. Development and Implementation of an Emergency Practitioner-Performed Brief Intervention for Harmful and Hazardous Drinkers in the Emergency Department. Academic Emergency Medicine. 2005; 12(3):249-256.

    O’Connor PG. Methods of Detoxification and Their Role in Managing Patients With Opioid Dependence. JAMA. 2005; 294(8):961-963.

    Sullivan LE, Fiellin DA, O’Connor PG. The prevalence and impact of alcohol problems in major depression: A systematic review. American Journal ofMedicine. 2005; 118(4):330-341.

    Kernan WE, Holmboe E, O’Connor PG. Assessing the teaching behaviors of ambulatory care preceptors. Academic Medicine. 2004; 79(11):1088-1094.

    O’Malley S, Rounsaville BJ, Farren C, Namkoong K, Wu R, Robinson J, O’Connor PG. Initial and Maintenance Naltrexone for Alcohol dependence using primary care vs. specialty care: A nested sequence of three randomized trials. Archives of Internal Medicine. 2003; 163(14):1695-1704.

    Kosten T, O’Connor PG. Current Concepts: Management of Drug and Alcohol Withdrawal. New England Journal of Medicine. 2003; 348(18):1786-1795.

    Reid MC, Engles-Horton LL, Weber MB, Kerns RD, Rogers EL, O’Connor PG. Use of opioid medications for chronic noncancer pain syndromes in primary care. Journal of General Internal Medicine. 2002; 17(3):173-9.

    O’Connor PG. Treating opioid dependence—new data and new opportunities. The New England Journal of Medicine. 2000; 343(18):1332-4.

    Fiellin DA, Reid MC, O’Connor PG. Screening for alcohol problems in primary care: A systematic review. Archives of Internal Medicine. 2000; 160(13):1977-89.

    O’Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Annals of Internal Medicine. 2000; 133(1):40-54.

    D’Onofrio G, Fiellin DA, Pantalon MV, Chawarski MC, Owens P, Degutis LC, Busch SH, Bernstein SL, O’Connor PG. A brief intervention reduces hazardous and harmful drinking in emergency department patients. Annals of Emergency Medicine 2012, 60:181-192. PMID: 22459448.

    Moore BA, Barry DT, Sullivan LE, O'Connor PG, Cutter CJ, Schottenfeld RS, Fiellin DA.Counseling and directly observed medication for primary care buprenorphine maintenance: a pilot study. Journal of Addiction Medicine 2012, 6(3):205-211. PMID: 22614936.

    Tetrault JM, Moore BA, Barry DT, O’Connor PG, Schottenfeld R, Fiellin DA, Fiellin LE. Brief versus extended counseling along with buprenorphone/naloxone for HIV-infected opioid dependent patients. Journal of Substance Abuse Treatment 2012, 43(4):433-439. PMID: 22938914.

    Fiellin DA, Barry DT, Sullivan LE, Cutter CJ, Moore BA, O’Connor PG, Schottenfeld RS. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. American Journal of Medicine 2013, 126(1):74-9. PMID: 23260506.

    O’Connor PG. Managing substance dependence as a chronic disease: is the glass half full or half empty? JAMA 2013, 310(11):1132-4. PMID: 24045739.

    Edelman EJ, Chantarat T, Caffrey S, Chaudhry A, O'Connor PG, Weiss L, Fiellin DA, Fiellin LE. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients. Drug and Alcohol Dependence 2014, 139:79-85. PMID: 24726429.

    Gueorguieva R, Wu R, O’Connor PG, Weisner C, Fucito LM, Hoffman S, Mann K, O’Malley SS. Predictors of abstinence from heavy drinking during treatment in COMBINE and external validation in PREDICT. Alcoholism: Clinical and Experimental Research 2014, 38(10):2647-2656. PMID: 25346505.

    O’Connor PG, Sokol RJ, D’Onofrio G. Addiction medicine: the birth of a new discipline. JAMA Internal Medicine 2014, 174(11):1717-1718. PMID: 25201642.

    Fiellin DA, Schottenfeld, RS, Cutter CJ, Moore BA, Barry DT, O’Connor PG. Primary care–based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Internal Medicine 2014, 174(12):1947-54. PMID: 25330017

    Tetrault JM, O’Connor PG. Unhealthy alcohol use, including alcohol use disorder: Epidemiology, pathogenesis, clinical manifestations, course assessment, and diagnosis. UpToDate 20

    Bagley S, Peterson J, Cheng DM, Jose C, Quinn E, O’Connor PG, Walley AY. Overdose Education and Naloxone Rescue Kits for Family Members of Individuals Who Use Opioids: Characteristics, Motivations, and Naloxone Use. Substance Abuse 2015, 36(2):149-54. PMID: 25564892.

    Fiellin D, Samet J, O’Connor PG. Addressing bias in observational studies of alcohol withdrawal syndrome: a call to the field. Alcoholism: Clinical and Experimental Research 2015, 39(2):390. PMID: 25665029.

    D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, Bernstein SL, Fiellin DA. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015, 313(16):1636-44. PMID: 25919527.

    O’Connor PG. Alcohol use disorder. In Goldman-Cecil Medicine, 25th Edition, 2015:149-156.

    Gueorguieva R, Wu R, Tsai W, O’Connor PG,Fucito L, Zhang H, O’Malley SS.An analysis of moderators in the COMBINE Study: Identifying subgroups of patients who benefit from acamprosate. European Neuropsychopharmacology. 2015 Oct;25(10):1586-99. PMID: 26141511.

    Edelman EJ, Hansen NB, Cutter CJ, Danton, C, Fiellin LE, O'Connor PG, Williams EC, Maisto SA, Bryant K, Fiellin DA. Implementation of Integrated Stepped Care for Unhealthy Alcohol Use in HIV Clinics. Addiction Science and Clinical Practice. 2016 Jan 13, 11: 1. PMID: 26763048.



    Education:

    B.S., Union College, 1978
    M.D., The Albany Medical College, 1982
    M.P.H., Yale University School of Medicine, 1988

    Training:

    Internal Medicine Residency: The University of Rochester School of Medicine and Dentistry, 1982-1985

    Chief Residency: The University of Rochester School of Medicine and Dentistry, 1985-1986

    Fellowship: The Robert Wood Johnson Clinical Scholars Program, Yale University, 1986-1988

  • Duffy Firm (Hematology)

    After completing his doctorate in medical hematology and oncology in Lyon, France, Dr. Prebet joined Institut Paoli-Calmettes in Marseille, France and completed a fellowship in Johns Hopkins University (Baltimore, MA, USA) as a Fullbright alumni. Dr. Prebet is currently the director of the inpatient hematology unit and the medical director of the hematology division of Yale Clinical Trial Office. He is the associate director of the myeloid malignancies program in the hematology department of the Yale Cancer Center, New haven, CT. He is developing myeloid malignancies clinical trials and translational works for advanced phase acute myeloid leukemia and myelodysplastics syndromes. The current works gave the basis for defining demethylating agent failure outcome (Prebet JCO 2011, Hematologica 2012, British Journal of Hematology 2012, Blood Advance 2018), contributed to his knowledge of combinations therapies based on HDAC inhibitors (Prebet JCO 2014, Prebet Leuk Res 2014) and gave the first insights on the implication of Wnt non canonical pathway in acute myeloid leukemia (Prebet Blood 2011). Dr Prebet is the coordinating investigator of several clinical trials for myelodysplastic syndromes and acute leukemia patients and contributed to 110 peer reviewed manuscript.

  • Donaldson Firm (HIV/ID)

    Dr. Villanueva is Director of the HIV/AIDS Program and Associate Professor of Medicine at Yale University School of Medicine. She obtained her undergraduate degree at Harvard University and MD at Washington University. She completed Internal Medicine Residency training at Duke University and subspecialty fellowship training in Infectious Diseases at Yale.

    After fellowship, she left academia to work at Waterbury Hospital, a community hospital, where she was Chief of Infectious Diseases. During this time, she established the Ryan White-funded HIV clinic which worked closely with community based AIDS organizations. Her experience in promoting collaborations became the basis for subsequent research interests and her recruitment back to Yale.

    A major focus of her academic work has been on developing HIV educational curricula for medical providers including Yale house staff and community providers throughout CT. She also serves as the Principal Investigator for the New Haven Ryan White HIV Continuum, a collaboration between different clinics and community organizations which promotes service coordination to improve quality of care for HIV patients, particularly those that are underserved. Her research interests focus on optimizing models of care that capitalize on partnerships between the medical establishment and community support.

  • Peters Firm (Renal)

    Dr. Brewster is a clinician educator in the Department of Medicine. She did her undergraduate work at Yale college and then went to Dartmouth Medical School. Her Internal Medicine Internship and Residency was at Yale New Haven Hospital. Following this, she did her fellowship at Yale in Nephrology and stayed on as faculty in the Nephrology Section.
    As a clinician-educator, Dr. Brewster's focus is primarily on the care of patients with kidney disease and on the education of the fellows and housestaff. She functions as the Program Director for the Nephrology Fellowship program and is the Firm Chief of the Peters Medical Firm, a medical house staff teaching firm dedicated to the specialized care of patients with kidney disease.
    In her clinical practice, she is a general nephrologist, seeing patients with chronic kidney disease or electrolyte disturbances, but has a subspecialized interest in the care of pregnant women with underlying kidney disease or hypertension. She practices both in the outpatient Yale Nephrology clinic, as well as on the inpatient acute nephrology consultative services. She is dedicated to the care of patients with end-stage kidney disease, and so sees patients in the outpatient dialysis clinics locally - with a more focused interest on home dialysis therapies.

  • Oncology Firm

    I was the principal clinical investigator of the Harvard UO1 Phase I program in 1995, uniting the clinical efforts at the DFCI, BWH, MGH and BIDMC. In 1998, I became the Clinical Director of the Experimental Therapeutics Program for the Dana-Farber/Harvard Cancer Center. As Clinical Director, I assumed overall responsibility for the trials performed at the DF/HCC. In 2004 I assumed the responsibilities as the Clinical Director of the DFCI General Cancer Research Center at the Dana-Farber/ Brigham and Women’s Hospital. These clinical and basic research activities have involved collaboration with clinical and basic scientists at Harvard and elsewhere, the Cancer Therapy Evaluation Program of the National Cancer Institute, presentations at national and international meetings, and correspondence with a number of leaders in the field of cancer drug development.

    At AstraZeneca PLC, I was the Medical Science Director for AstraZeneca’s Boston site, responsible for the medical and clinical aspects of development of agents from chemical lead identification through clinical proof of concept in phase II. I was responsible for the design and interpretation of the entire clinical development plan for five agents. This position had global responsibilities with clinical trials in the US, Canada, European Union, Japan and Korea. I was a member of the Strategic Planning & Business Development as an ad hoc member and was the global Disease Area Clinical Expert for Hematology.

    At Yale I am Clinical Director of the Early Drug Development Program, performing Phase I clinical trials of new cancer medicines.